GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2013

Kemwell Biopharma Acquires Cirrus Pharmaceuticals

  • Bangalore, India-based biopharmaceutical contract services company Kemwell Biopharma has acquired contract development services firm Cirrus Pharmaceuticals, which is based in Research Triangle Park, NC. Financial terms were not disclosed.

    Cirrus was established in 1997 and offers an array of R&D services including physical and chemical characterization, formulation development, stability testing, container/closure selection, process development, scale-up and technical transfer for inhaled, nasal, oral, parenteral, topical, and transdermal products. The firm also offers stand-alone services, such as stability studies.

    “The acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms,” the firm’s president, Anthony Hickey, Ph.D., said in a statement.

    Added Kemwell’s chairman, Anurag Bagaria: “Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the U.S. to commercial manufacturing in Kemwell's EMA-, FDA-, and PMD-approved facilities in India and Sweden.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?